Trials / Withdrawn
WithdrawnNCT05943314
Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia
Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in Refractory/Recurrent Acute Myeloid Leukemia: a Single-arm, Non-blind Clinical Study
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd · Industry
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm, open, intravenous drug administration of the safety and efficacy of clinical study.
Detailed description
The primary objective of the clinical trial was to evaluate the safety and efficacy of single dose infusion of anti-CLL1 /+CD33 CAR T cells in patients with refractory/recurrent acute myeloid leukemia. A total of about 5 patients with refractory/recurrent acute myeloid leukemia were enrolled in this study, and the target dose range was 1.00\~2.50x10\^6/kgCAR-positive T cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CLL1/+CD33 CAR-T | CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia. |
Timeline
- Start date
- 2023-07-12
- Primary completion
- 2023-08-28
- Completion
- 2023-08-28
- First posted
- 2023-07-13
- Last updated
- 2023-11-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05943314. Inclusion in this directory is not an endorsement.